Charlottetown, P.E.I. (April 14, 2022) – BIOVECTRA broke ground today, with help from provincial and federal officials, on a cutting-edge facility that will manufacture mRNA vaccines and therapeutics starting in 2023.
BIOVECTRA’s mRNA Vaccine and Biomanufacturing Centre will add 36,000 square feet to its existing Charlottetown campus and, when operational, the cGMP facility will be able produce 160 million doses of mRNA vaccine and fill/finish 70 million final vaccine doses per year for commercial distribution.
“Today is the tangible beginning to a very exciting future for our company,” explains Oliver Technow, CEO BIOVECTRA. “This biomanufacturing centre is the cornerstone of BIOVECTRA’s expansion plans for an end-to-end solution to produce mRNA vaccines and therapies.”
“We appreciate the support from all levels of government as well as the interest this expansion has generated both within our local communities and throughout North America,” added Mr. Technow.
The company previously announced its $79.6 million expansion of its business to produce mRNA vaccines and therapeutics, with the Government of Canada contributing $39.8 million through the Strategic Innovation Fund and a $10 million investment from the Province of Prince Edward Island back in November 2021. At least 125 new highly skilled jobs and 220 Co-op placements will be created in both Prince Edward Island and Nova Scotia.
“BIOVECTRA is a true leader in bioscience research and innovation, and we’re so proud they call the east coast home,” said Premier Dennis King.
The expansion also includes completing a Single-Use Clinical Scale Microbial Suite in Windsor, Nova Scotia this summer (2022), as well as opening a research and development facility in Halifax, Nova Scotia. The addition to BIOVECTRA’s Windsor site supports the development and production of plasmid DNA, the key ingredient to manufacture mRNA therapeutics and vaccines. BIOVECTRA will also start to develop and manufacture nucleic acids and add additional capacity for advancing microbial protein and other Biotherapeutics via microbial fermentation.
“As a Canadian company, BIOVECTRA is honoured to help our country face future pandemics, while also creating the versatile technology platforms that can help clients deliver the treatments that will become the next generation of patient care,” explained Mr. Technow.
BIOVECTRA is a global biotech and pharmaceutical CDMO (contract development and manufacturing organization) that specializes in clinical-to-commercial scale production capabilities for: biologics, small molecules, bioreagents, and pDNA and MRNA manufacturing. Flexibility, creativity, process optimization and compliance are at the heart of our method. With more than 50 years of experience, over 550 employees, and cGMP facilities in Prince Edward Island and Nova Scotia, Canada we assure our programs advance on time and with the highest quality outcomes.
Bobbi Jo Walker
Director, Corporate Communication